Cellular Health Market Leader Tru Niagen® Launches Online in Australia
March 23, 2020 06:30 ET
|
ChromaDex Corporation
ChromaDex Partners with Matakana Health Limited to Bring Tru Niagen to Australia LOS ANGELES, March 23, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today the e-commerce...
ChromaDex Corrects Statements Made by an Unaffiliated Third Party Regarding its Product and COVID-19
March 12, 2020 16:44 ET
|
ChromaDex Corporation
LOS ANGELES, March 12, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) seeks to correct statements made by an unaffiliated third-party, Merkel Media Group on behalf of its unnamed client,...
CHROMADEX CORPORATION REPORTS 2019 FINANCIAL RESULTS
March 10, 2020 16:01 ET
|
ChromaDex Corporation
Fourth Quarter 2019 Highlights vs. Fourth Quarter 2018 Strong growth in net sales to $13.1 million, higher gross margins, and significantly improved marketing efficiency year-over-year.Tru...
New Niagen® Nicotinamide Riboside (NR) Study Deepens Understanding of NAD Decline and Hearing Loss in Animal Model
February 27, 2020 06:30 ET
|
ChromaDex Corporation
LOS ANGELES, Feb. 27, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), a global scientific authority on nicotinamide adenine dinucleotide (NAD) and nicotinamide riboside (NR) science,...
ChromaDex to Report Fourth Quarter 2019 Financial Results on Tuesday, March 10, 2020
February 25, 2020 06:30 ET
|
ChromaDex Corporation
LOS ANGELES, Feb. 25, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Tues., Mar. 10, 2020 at 4:30 p.m. ET to discuss its financial results...
ChromaDex Partners with Personalized Nutrition Company, Persona Nutrition, Expanding Global Partnership with Nestlé Health Science
February 12, 2020 06:30 ET
|
ChromaDex Corporation
LOS ANGELES, Feb. 12, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) today announced the launch of its flagship cellular health supplement Tru Niagen® (nicotinamide riboside) as a supplement...
ChromaDex Launches New Line of High Purity Cannabinoid (CBD) Reference Standards Available for Research and Analytical Testing Worldwide
February 03, 2020 06:30 ET
|
ChromaDex Corporation
LOS ANGELES, Feb. 03, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) today announced the expansion of its industry-leading reference standards business with a new line of cannabinoid (CBD)...
ChromaDex Achieves New Regulatory Milestones in the European Union & Australia
January 15, 2020 06:30 ET
|
ChromaDex Corporation
LOS ANGELES, Jan. 15, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) today announced regulatory authorizations to sell its patented nicotinamide riboside chloride (NR, or Niagen®) to...
First-of-its-Kind Clinical Study Initiated to Investigate Potential Benefits of Nicotinamide Riboside Combined with Exercise in Older Adults with Hypertension
January 06, 2020 06:30 ET
|
ChromaDex Corporation
LOS ANGELES, Jan. 06, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), the global scientific authority on nicotinamide adenine dinucleotide (NAD) and nicotinamide riboside (NR) science,...
ChromaDex Wins Nutritional Outlook’s 2019 “Best of Industry” Ingredient Supplier Award for Niagen®
December 16, 2019 06:30 ET
|
ChromaDex Corporation
LOS ANGELES, Dec. 16, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that Nutritional Outlook®, a leading publication for the nutraceuticals industry, recently awarded...